CoChat

Aberrant ERBB4-SRC Signaling as a Hallmark of Group 4 Medulloblastoma Revealed by Integrative Phosphoproteomic Profiling

Open access
Forget, Antoine, Martignetti, Loredana, Puget, Stéphanie, Calzone, Laurence, Brabetz, Sebastian, Picard, Daniel, Montagud, Arnau, Liva, Stéphane, Sta, Alexandre, Dingli, Florent, Arras, Guillaume, Rivera, Jaime, Loew, Damarys, Besnard, Aurore, Lacombe, Joëlle, Pagès, Mélanie, Varlet, Pascale, Dufour, Christelle, Yu, Hua, Mercier, Audrey L., Indersie, Emilie, Chivet, Anaïs, Leboucher, Sophie, Sieber, Laura, Beccaria, Kevin, Gombert, Michael, Meyer, Frauke D., Qin, Nan, Bartl, Jasmin, Chavez, Lukas, Okonechnikov, Konstantin, Sharma, Tanvi, Thatikonda, Venu, Bourdeaut, Franck, Pouponnot, Celio, Ramaswamy, Vijay, Korshunov, Andrey, Borkhardt, Arndt, Reifenberger, Guido, Poullet, Patrick, Taylor, Michael D., Kool, Marcel, Pfister, Stefan M., Kawauchi, Daisuke, Barillot, Emmanuel, Remke, Marc, Ayrault, Olivier · 2018 · Cancer Cell
Cited by 142

The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.

Abstract

The current consensus recognizes four main medulloblastoma subgroups (wingless, Sonic hedgehog, group 3 and group 4). While medulloblastoma subgroups have been characterized extensively at the (epi-)genomic and transcriptomic levels, the proteome and phosphoproteome landscape remain to be comprehensively elucidated. Using quantitative (phospho)-proteomics in primary human medulloblastomas, we unravel distinct posttranscriptional regulation leading to highly divergent oncogenic signaling and kinase activity profiles in groups 3 and 4 medulloblastomas. Specifically, proteomic and phosphoproteomic analyses identify aberrant ERBB4-SRC signaling in group 4. Hence, enforced expression of an activated SRC combined with p53 inactivation induces murine tumors that resemble group 4 medulloblastoma. Therefore, our integrative proteogenomics approach unveils an oncogenic pathway and potential therapeutic vulnerability in the most common medulloblastoma subgroup.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ccell.2018.08.002

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 60

  1. Araki, 2015, Inhibitors of CLK protein kinases suppress cell growth and induce apoptosis by modulating pre-mRNA splicing, PLoS One, 10, e0116929, 10.1371/journal.pone.0116929 · DOI
  2. Archer, 2018, Proteomics, post-translational modifications, and integrative analyses reveal heterogeneity of molecular mechanisms within medulloblastoma subgroups, Cancer Cell, 34, 396, 10.1016/j.ccell.2018.08.004 · DOI · Paper page
  3. Bennetzen, 2012, PhosphoSiteAnalyzer: a bioinformatic platform for deciphering phospho proteomes using kinase predictions retrieved from NetworKIN, J. Proteome Res., 11, 3480, 10.1021/pr300016e · DOI
  4. Bian, 2013, Global screening of CK2 kinase substrates by an integrated phosphoproteomics workflow, Sci. Rep., 3, 3460, 10.1038/srep03460 · DOI
  5. Cho, 2011, Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome, J. Clin. Oncol., 29, 1424, 10.1200/JCO.2010.28.5148 · DOI · Paper page
  6. Chou, 2011, Biological sequence motif discovery using motif-x, Curr. Protoc. Bioinformatics, 13, 15
  7. Clifford, 2006, Wnt/Wingless pathway activation and chromosome 6 loss characterize a distinct molecular sub-group of medulloblastomas associated with a favorable prognosis, Cell Cycle, 5, 2666, 10.4161/cc.5.22.3446 · DOI · Paper page
  8. Dobin, 2013, STAR: ultrafast universal RNA-seq aligner, Bioinformatics, 29, 15, 10.1093/bioinformatics/bts635 · DOI · Paper page
  9. Durinck, 2009, Mapping identifiers for the integration of genomic datasets with the R/Bioconductor package biomaRt, Nat. Protoc., 4, 1184, 10.1038/nprot.2009.97 · DOI · Paper page
  10. Fabregat, 2016, The reactome pathway knowledgebase, Nucleic Acids Res., 44, D481, 10.1093/nar/gkv1351 · DOI · Paper page
  11. Fan, 2016, Characterizing transcriptional heterogeneity through pathway and gene set overdispersion analysis, Nat. Methods, 13, 241, 10.1038/nmeth.3734 · DOI · Paper page
  12. Geiger, 2010, Super-SILAC mix for quantitative proteomics of human tumor tissue, Nat. Methods, 7, 383, 10.1038/nmeth.1446 · DOI · Paper page
  13. Geiger, 2011, Use of stable isotope labeling by amino acids in cell culture as a spike-in standard in quantitative proteomics, Nat. Protoc., 6, 147, 10.1038/nprot.2010.192 · DOI · Paper page
  14. Gilbertson, 1998, Expression of the ErbB-neuregulin signaling network during human cerebellar development: implications for the biology of medulloblastoma, Cancer Res., 58, 3932
  15. Gilbertson, 1997, Prognostic significance of HER2 and HER4 coexpression in childhood medulloblastoma, Cancer Res., 57, 3272
  16. Gottardo, 2014, Medulloblastoma down under 2013: a report from the third annual meeting of the International Medulloblastoma Working Group, Acta Neuropathol., 127, 189, 10.1007/s00401-013-1213-7 · DOI
  17. Guo, 2017, Proteasome activator subunit 3 promotes pancreatic cancer growth via c-Myc-glycolysis signaling axis, Cancer Lett., 386, 161, 10.1016/j.canlet.2016.08.018 · DOI
  18. Horn, 2014, KinomeXplorer: an integrated platform for kinome biology studies, Nat. Methods, 11, 603, 10.1038/nmeth.2968 · DOI · Paper page
  19. Hovestadt, 2014, Decoding the regulatory landscape of medulloblastoma using DNA methylation sequencing, Nature, 510, 537, 10.1038/nature13268 · DOI · Paper page
  20. Hovestadt, 2013, Robust molecular subgrouping and copy-number profiling of medulloblastoma from small amounts of archival tumour material using high-density DNA methylation arrays, Acta Neuropathol., 125, 913, 10.1007/s00401-013-1126-5 · DOI · Paper page
  21. Karaki, 2015, The eukaryotic translation initiation factor 4E (eIF4E) as a therapeutic target for cancer, Adv. Protein Chem. Struct. Biol., 101, 1, 10.1016/bs.apcsb.2015.09.001 · DOI
  22. Kawauchi, 2017, Novel MYC-driven medulloblastoma models from multiple embryonic cerebellar cells, Oncogene, 36, 5231, 10.1038/onc.2017.110 · DOI
  23. Kool, 2014, Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition, Cancer Cell, 25, 393, 10.1016/j.ccr.2014.02.004 · DOI · Paper page
  24. Kool, 2012, Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas, Acta Neuropathol., 123, 473, 10.1007/s00401-012-0958-8 · DOI · Paper page
  25. Kool, 2008, Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features, PLoS One, 3, e3088, 10.1371/journal.pone.0003088 · DOI · Paper page
  26. Lan, 2017, Downregulation of β-arrestin 1 suppresses glioblastoma cell malignant progression vis inhibition of Src signaling, Exp. Cell Res., 357, 51, 10.1016/j.yexcr.2017.04.023 · DOI
  27. Langmead, 2012, Fast gapped-read alignment with Bowtie 2, Nat. Methods, 9, 357, 10.1038/nmeth.1923 · DOI · Paper page
  28. Lin, 2016, Active medulloblastoma enhancers reveal subgroup-specific cellular origins, Nature, 530, 57, 10.1038/nature16546 · DOI · Paper page
  29. Louis, 2016, The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary, Acta Neuropathol, 131, 803, 10.1007/s00401-016-1545-1 · DOI · Paper page
  30. Martignetti, 2016, ROMA: representation and quantification of module activity from target expression data, Front. Genet., 7, 18, 10.3389/fgene.2016.00018 · DOI
  31. Milde, 2012, HD-MB03 is a novel Group 3 medulloblastoma model demonstrating sensitivity to histone deacetylase inhibitor treatment, J. Neurooncol., 110, 335, 10.1007/s11060-012-0978-1 · DOI
  32. Northcott, 2011, Medulloblastoma comprises four distinct molecular variants, J. Clin. Oncol., 29, 1408, 10.1200/JCO.2009.27.4324 · DOI · Paper page
  33. Northcott, 2012, Rapid, reliable, and reproducible molecular sub-grouping of clinical medulloblastoma samples, Acta Neuropathol., 123, 615, 10.1007/s00401-011-0899-7 · DOI · Paper page
  34. Obara, 2004, PKA phosphorylation of Src mediates Rap1 activation in NGF and cAMP signaling in PC12 cells, J. Cell Sci., 117, 6085, 10.1242/jcs.01527 · DOI · Paper page
  35. Pei, 2012, An animal model of MYC-driven medulloblastoma, Cancer Cell, 21, 155, 10.1016/j.ccr.2011.12.021 · DOI · Paper page
  36. Pfister, 2009, Outcome prediction in pediatric medulloblastoma based on DNA copy-number aberrations of chromosomes 6q and 17q and the MYC and MYCN loci, J. Clin. Oncol., 27, 1627, 10.1200/JCO.2008.17.9432 · DOI · Paper page
  37. Poullet, 2007, myProMS, a web server for management and validation of mass spectrometry-based proteomic data, Proteomics, 7, 2553, 10.1002/pmic.200600784 · DOI · Paper page
  38. Remke, 2011, FSTL5 is a marker of poor prognosis in non-WNT/non-SHH medulloblastoma, J. Clin. Oncol., 29, 3852, 10.1200/JCO.2011.36.2798 · DOI · Paper page
  39. Remke, 2011, Adult medulloblastoma comprises three major molecular variants, J. Clin. Oncol., 29, 2717, 10.1200/JCO.2011.34.9373 · DOI · Paper page
  40. Ritchie, 2015, Limma powers differential expression analyses for RNA-sequencing and microarray studies, Nucleic Acids Res., 43, e47, 10.1093/nar/gkv007 · DOI · Paper page
  41. Robinson, 2012, Novel mutations target distinct subgroups of medulloblastoma, Nature, 488, 43, 10.1038/nature11213 · DOI · Paper page
  42. Sato, 2007, Stable integration and conditional expression of electroporated transgenes in chicken embryos, Dev. Biol., 305, 616, 10.1016/j.ydbio.2007.01.043 · DOI · Paper page
  43. Schwalbe, 2017, Novel molecular subgroups for clinical classification and outcome prediction in childhood medulloblastoma: a cohort study, Lancet Oncol., 18, 958, 10.1016/S1470-2045(17)30243-7 · DOI · Paper page
  44. Schwalbe, 2013, DNA methylation profiling of medulloblastoma allows robust subclassification and improved outcome prediction using formalin-fixed biopsies, Acta Neuropathol., 125, 359, 10.1007/s00401-012-1077-2 · DOI · Paper page
  45. Shannon, 2003, Cytoscape: a software environment for integrated models of biomolecular interaction networks, Genome Res., 13, 2498, 10.1101/gr.1239303 · DOI · Paper page
  46. Shih, 2014, Cytogenetic prognostication within medulloblastoma subgroups, J. Clin. Oncol., 32, 886, 10.1200/JCO.2013.50.9539 · DOI · Paper page
  47. Sturm, 2016, New brain tumor entities emerge from molecular classification of CNS-PNETs, Cell, 164, 1060, 10.1016/j.cell.2016.01.015 · DOI · Paper page
  48. Sugimura, 2000, Mutation of the SRC gene in endometrial carcinoma, Jpn. J. Cancer Res., 91, 395, 10.1111/j.1349-7006.2000.tb00958.x · DOI · Paper page
  49. Taus, 2011, Universal and confident phosphorylation site localization using phosphoRS, J. Proteome Res., 10, 5354, 10.1021/pr200611n · DOI · Paper page
  50. Thompson, 2006, Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations, J. Clin. Oncol., 24, 1924, 10.1200/JCO.2005.04.4974 · DOI · Paper page
  51. Thoreen, 2017, The molecular basis of mTORC1-regulated translation, Biochem. Soc. Trans., 45, 213, 10.1042/BST20160072 · DOI · Paper page
  52. Truitt, 2017, New frontiers in translational control of the cancer genome, Nat. Rev. Cancer, 17, 332, 10.1038/nrc.2017.30 · DOI · Paper page
  53. Vizcaino, 2016, 2016 update of the PRIDE database and its related tools, Nucleic Acids Res., 44, 11033, 10.1093/nar/gkw880 · DOI · Paper page
  54. Wang, 2016, Transactivation of epidermal growth factor receptor by G protein-coupled receptors: recent progress, challenges and future research, Int. J. Mol. Sci., 17, 95, 10.3390/ijms17010095 · DOI
  55. Wefers, 2014, Subgroup-specific localization of human medulloblastoma based on pre-operative MRI, Acta Neuropathol., 127, 931, 10.1007/s00401-014-1271-5 · DOI
  56. Zaiss, 1999, The proteasome inhibitor PI31 competes with PA28 for binding to 20S proteasomes, FEBS Lett., 457, 333, 10.1016/S0014-5793(99)01072-8 · DOI · Paper page
  57. Zhang, 2016, Integrated proteogenomic characterization of human high-grade serous ovarian cancer, Cell, 166, 755, 10.1016/j.cell.2016.05.069 · DOI · Paper page
  58. Zhang, 2004, Shp2 regulates SRC family kinase activity and Ras/Erk activation by controlling Csk recruitment, Mol. Cell, 13, 341, 10.1016/S1097-2765(04)00050-4 · DOI · Paper page
  59. Zomerman, 2018, Identification of two protein-signaling states delineating transcriptionally heterogeneous human medulloblastoma, Cell Rep., 22, 3206, 10.1016/j.celrep.2018.02.089 · DOI
  60. Zuckermann, 2015, Somatic CRISPR/Cas9-mediated tumour suppressor disruption enables versatile brain tumour modelling, Nat. Commun., 6, 7391, 10.1038/ncomms8391 · DOI · Paper page

Cited by

See all 142

Metadata

Authors
Forget, A., Martignetti, L., Puget, S., Calzone, L., Brabetz, S., Picard, D., Montagud, A., Liva, S., Sta, A., Dingli, F., Arras, G., Rivera, J., Loew, D., Besnard, A., Lacombe, J., Pagès, M., Varlet, P., Dufour, C., Yu, H., Mercier, A. L., Indersie, E., Chivet, A., Leboucher, S., Sieber, L., Beccaria, K., Gombert, M., Meyer, F. D., Qin, N., Bartl, J., Chavez, L., Okonechnikov, K., Sharma, T., Thatikonda, V., Bourdeaut, F., Pouponnot, C., Ramaswamy, V., Korshunov, A., Borkhardt, A., Reifenberger, G., Poullet, P., Taylor, M. D., Kool, M., Pfister, S. M., Kawauchi, D., Barillot, E., Remke, M., & Ayrault, O.
Venue
Cancer Cell
Publisher
Elsevier BV
Published
2018-09
Volume
34
Issue
3
Pages
379-395.e7
ISSN
1535-6108 (ISSN-L)
OpenAlex
W2892282588
Cited by
142
References
25
FWCI
8.59
Type
journal article
Language
en
Open access
bronze
Licence
Funders
  • ITMO Cancer
  • Paris Alliance of Cancer Research Institutes
  • Ministère Français de l'Enseignement Supérieur et de la Recherche
  • Fondation de France
  • King Baudouin Foundation
  • Fondation ARC pour la Recherche sur le Cancer (20141201848)
  • Ligue Nationale Contre le Cancer
  • CNRS
  • Institut Curie
  • Région Ile-de-France (2013-2-EML-02-ICR-1)
  • Deutsche Forschungsgemeinschaft (KA 4472/1-1)
  • Fondation pour la Recherche Médicale (DGE20121125630)
  • Brain Tumor Charity Collaborative Team (GN-000356)
  • Pediatric Brain Tumor Foundation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.